Sanja Pekovic - Hard To Chief Scientist
Insider
Sanja Pekovic is Chief Scientist of Hard to Treat
| Address | Room EF, 12F, Shenzhen, China, 518040 |
| Phone | 86 755 8272 0498 |
| Web | https://www.mellowhope.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jason Barker | Arcus Biosciences | 49 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Nicole Lambert | Arcus Biosciences | 46 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Sunil MD | Sana Biotechnology | 54 | |
| Shanna Peek | Sana Biotechnology | N/A | |
| Edward III | Fate Therapeutics | 48 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Jonathan Yingling | Arcus Biosciences | 55 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Michael Quigley | Arcus Biosciences | 38 | |
| James JD | Karyopharm Therapeutics | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Bernard JD | Sana Biotechnology | 69 | |
| Mansoor MD | Karyopharm Therapeutics | 63 | |
| Linda Higgins | Arcus Biosciences | N/A | |
| Mark DVM | Fate Therapeutics | 63 | |
| Merdad Parsey | Arcus Biosciences | 58 | |
| Syed MD | Caribou Biosciences | 57 | |
| Joern Aldag | Hookipa Pharma | 65 | |
Hard to Treat Leadership Team
Elected by the shareholders, the Hard To's board of directors comprises two types of representatives: Hard To inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hard. The board's role is to monitor Hard To's management team and ensure that shareholders' interests are well served. Hard To's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hard To's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shimin Yuan, Chief Officer | ||
| Carol Roberts, Sec | ||
| Sanja Pekovic, Chief Scientist | ||
| Ivana Gadjanski, Communication Director |
Hard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hard To a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 254.37 K | ||||
| Shares Outstanding | 5.48 B | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 5.39 M | ||||
| Gross Profit | 1.42 M | ||||
| EBITDA | 1.03 M | ||||
| Net Income | 621.6 K | ||||
| Cash And Equivalents | 202.9 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hard Stock Analysis
When running Hard To's price analysis, check to measure Hard To's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hard To is operating at the current time. Most of Hard To's value examination focuses on studying past and present price action to predict the probability of Hard To's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hard To's price. Additionally, you may evaluate how the addition of Hard To to your portfolios can decrease your overall portfolio volatility.